Advanced search

Find pages with...
Then narrow your results by...

About 76 search results

Search results

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/search-recherche/simple?js_en=&page=1000&per_page=7000&plain_text=&s=

Mar 30, 2012 ... PREFORMED ARCHWIRE, 40C, .016X .022 LO PK 10 (2015-11-02) Affected Products COPPER NITI PREFORMED ARCHWIRE, 40C, .016X .022 LO PK 10 The product transformation temperature as listed on the labelling is not correct. The wire is labelled as having a 40°C transformation temperature, but... Posted: 2015-11-02 Type of communication: Recall OPTISURE DEFIBRILLATION LEAD

Search results

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/search-recherche/simple?js_en=&page=1000&per_page=10000&plain_text=&s=

Mar 30, 2012 ...: 2014-07-08 Type of communication: Recall Citalopram-10, Methylphenidate recall (2014-07-08) Citalopram-10, Methylphenidate recall (2014-07-08) Recalled Products Citalopram-10 Methylphenidate The recall of lot #481820 was initiated following the discovery of two bottles of the product Methylphenidate (5 mg) labelled as Citalopram-10. It was confirmed

Meridia (sibutramine) Capsules - Voluntary Withdrawal from the Canadian Market - For Health Professionals

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/14614a-eng.php

... events. The majority of the patients enrolled had underlying cardiovascular disease and were not eligible to receive sibutramine under the current labeling. In the study, these high-risk cardiovascular patients were treated with sibutramine for up to 6 years. Patients treated with sibutramine experienced a 16% increased risk of a primary outcome event of non

Search results

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/search-recherche/simple?js_en=&page=1000&per_page=3000&plain_text=&s=

Mar 30, 2012 ... of many Canadians from all walks of life. Patients receiving prescription opioids and treating physicians... Posted: 2017-12-08 Type of communication: Advisory CRYOcheck Factor II Deficient Plasma (2017-12-07) CRYOcheck Factor II Deficient Plasma (2017-12-07) Affected Products CRYOcheck Factor II Deficient Plasma Typographical error on the vial labels. Catalogue

Health Products that May Pose a Serious Risk to Health Removed From Vancouver Island Stores

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/13452a-eng.php

.... Reason The labels on some of these products indicate they contain ingredients that legally require the products to be sold by prescription because they are used to treat serious diseases or may have side effects that require monitoring by a health care practitioner. What you should do Consult your healthcare practitioner if you have used any of these products

MIFEGYMISO (mifepristone and misoprostol tablets) - Updates to Product Monograph and Risk Management Plan

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65030a-eng.php

... until updated labelling is made available. Celopharma has committed to update these documents by summer 2018. Other available resources Celopharma's toll-free line 1-877-230-4227 will be available to provide general information to patients or health professionals on MIFEGYMISO. Report health or safety concerns Managing marketed health product-related side

Archive – Health Canada Advises Consumers to Verify their Medication

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2005/13675a-eng.php

... request alternate formats by contacting us. Archive – Health Canada Advises Consumers to Verify their Medication Report a Concern Starting date: April 22, 2005 Posting date: April 22, 2005 Type of communication: Advisory Subcategory: Drugs Source of recall: Health Canada Issue: Product Safety, Labelling and Packaging Audience: General Public, Healthcare

YERVOY 200 mg/40 mL (5 mg/mL) (Ipilimumab for injection), single-use vial - Recall of 2 Lots Due to Cracked Vials - Notice to Hospitals

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/41861a-eng.php

... to patients with respect to loss of sterility, the likelihood of such occurrence is extremely low due to the fact that the safety assessment conducted did not find any adverse reports potentially related to cracked vials. In addition, the product label has clear instructions on how to inspect the vial during preparation which will prevent inadvertent use of a vial

CANCIDAS (caspofungin acetate for injection) - Voluntary Product Recall - Notice to Hospitals

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/14594a-eng.php

... Vigilance Program Marketed Health Products Directorate Health Canada Address Locator: 0701E Ottawa, Ontario, K1A 0K9 Telephone: 613-957-0337 or Fax: 613-957-0335 CanadaVigilance@hc-sc.gc.ca To report an Adverse Reaction, consumers and health professionals may call toll free: Telephone: 1-866-234-2345 Fax: 1-866-678-6789 Postage paid labels, the Canada Vigilance

Search results

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/search-recherche/simple?js_en=&page=1000&per_page=29000&plain_text=&s=

Mar 30, 2012 ...Search interface for Health Canada website

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: